Irina Ishak Counsel

New Jersey
T 973.422.6406 | F 973.422.6407

Irina focuses on life sciences companies and has a strong track record in all areas of capital markets, public reporting, structuring and negotiating complex agreements, public and private financings, and mergers and acquisitions. She also advises clients regarding corporate strategies and governance.

Prior to joining Lowenstein Sandler, Irina served as Senior Director, Legal Assistant Corporate Secretary for Savient Pharmaceuticals Inc., a specialty biopharmaceutical company. Her responsibilities there included a broad spectrum of corporate compliance, pharma-compliance, and transactional matters. Irina has extensive experience working across functional groups to further the clinical development and launch of pharmaceutical products. Previously, she handled complex corporate and commercial matters for large law firms, where her clients ranged from startups to multinational conglomerates.

Press Mentions

Lowenstein Sandler represented Emisphere Technologies, Inc. in their development and license agreement with Novo Nordisk A/S, a global healthcare company that focuses on the development of products to benefit people with diabetes and other serious chronic conditions. Novo Nordisk A/S will develop and commercialize oral formulations of four classes of investigational molecules targeting major metabolic disorders, specifically diabetes and obesity, using Emisphere's oral Eligen® Technology. Terms of the agreement grant Novo Nordisk the exclusive right to develop potential product candidates in three molecule classes through Emisphere’s licensing, and the non-exclusive right to develop potential product candidates in a fourth molecule class, using the Eligen® Technology. The Lowenstein deal team included Michael J. LernerIrina Ishak and Herschel S. Weinstein. , October 15, 2015
Lowenstein Sandler represented underwriters Roth Capital Partners LLC, Oppenheimer & Company Inc., and Janney Montgomery Scott LLC in connection with Tonix Pharmaceuticals Holding Corp (TNXP) $20.1 million public offering of common stock. The Lowenstein deal team included John (Jack) D. Hogoboom, Ellen Santos, Albert Alsaygh, Rob Paradiso and Irina Ishak. , July 17, 2015
Lowenstein Sandler represented Maxim Group LLC, as placement agent, in connection with a registered direct offering of $4 million for Rock Creek Pharmaceuticals. The Lowenstein deal team included Steven M. Skolnick, Robert J. ParadisoIrina Ishak and Brandon Greenblatt. , June 18, 2015
View More...

Related Areas

Life Sciences


New York University School of Law ( J.D. , 1999 ) , Editor, Review of Law & Social Change
Rutgers, The State University of New Jersey ( B.A. , 1995 ) , with highest honors

Bar Admissions

New York
New Jersey